<?xml version='1.0' encoding='utf-8'?>
<document id="29626533"><sentence text="The Repurposing of Ivermectin for Malaria: A Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing Regimen Options."><entity charOffset="19-29" id="DDI-PubMed.29626533.s1.e0" text="Ivermectin" /></sentence><sentence text="Ivermectin has demonstrated many successes in the treatment of a range of nematode infections"><entity charOffset="0-10" id="DDI-PubMed.29626533.s2.e0" text="Ivermectin" /></sentence><sentence text=" Considering the increase in malaria resistance, attention has turned toward ivermectin as a candidate for repurposing for malaria"><entity charOffset="77-87" id="DDI-PubMed.29626533.s3.e0" text="ivermectin" /></sentence><sentence text=" This study developed and validated an ivermectin physiology-based pharmacokinetic model in healthy adults (20-50 years), pediatric (3-5 years/15-25 kg) subjects, and a representative adult malaria population group (Thailand)"><entity charOffset="39-49" id="DDI-PubMed.29626533.s4.e0" text="ivermectin" /></sentence><sentence text=" Dosing optimization demonstrating a twice-daily dose for 3- or 5-day regimens would provide a time above the LC50 of more than 7 days for adult and pediatric subjects" /><sentence text=" Furthermore, to address the occurrence of CYP450 induction that is often encountered with antiretroviral agents, simulated drug-drug interaction studies with efavirenz highlighted that a 1-mg/kg once-daily dose for 5 days would counteract the increased ivermectin hepatic clearance and enable a time above LC50 of 138"><entity charOffset="159-168" id="DDI-PubMed.29626533.s6.e0" text="efavirenz" /><entity charOffset="254-264" id="DDI-PubMed.29626533.s6.e1" text="ivermectin" /><pair ddi="false" e1="DDI-PubMed.29626533.s6.e0" e2="DDI-PubMed.29626533.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29626533.s6.e0" e2="DDI-PubMed.29626533.s6.e1" /></sentence><sentence text="8 h in adults and 141" /><sentence text="2 h in pediatric subjects" /><sentence text=" It was also demonstrated that dosage regimen design would require consideration of the age-weight geographical relationship of the subjects, with a dosage regimen for a representative Thailand population group requiring at least a single daily dose for 5 days to maintain ivermectin plasma concentrations and a time above LC50 similar to that in healthy adults"><entity charOffset="273-283" id="DDI-PubMed.29626533.s9.e0" text="ivermectin" /></sentence><sentence text="" /></document>